P Roy Vagelos Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

P Roy Vagelos is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 312,578 shares of REGN, which is worth approximately $214 Million. The most recent transaction as insider was on Mar 23, 2023, when has been sold 25,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 313K

0% 3M change

0% 12M change

Total Value Held $214 Million

P ROY VAGELOS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 23 2023	SELL Bona fide gift	-	25,000 Reduced 7.41%	312,578 Common Stock
Feb 22 2023	SELL Payment of exercise price or tax liability	$21,758,390 $750.16 p/Share	29,005 Reduced 7.91%	337,578 Common Stock
Feb 22 2023	BUY Exercise of conversion of derivative security	$11,493,275 $270.43 p/Share	42,500 Added 10.39%	366,583 Common Stock
Dec 16 2022	BUY Grant, award, or other acquisition	-	1,651 Added 0.51%	324,083 Common Stock
Dec 09 2022	SELL Payment of exercise price or tax liability	$42,936 $753.28 p/Share	57 Reduced 0.02%	322,432 Common Stock
May 24 2022	SELL Bona fide gift	-	23,077 Reduced 6.68%	322,489 Common Stock
Mar 14 2022	SELL Payment of exercise price or tax liability	$31,521,414 $655.29 p/Share	48,103 Reduced 12.22%	345,566 Common Stock
Mar 14 2022	BUY Exercise of conversion of derivative security	$13,434,750 $179.13 p/Share	75,000 Added 16.0%	393,669 Common Stock
Dec 08 2021	BUY Grant, award, or other acquisition	-	1,861 Added 0.58%	318,669 Common Stock
Aug 25 2021	SELL Payment of exercise price or tax liability	$32,890,315 $667.39 p/Share	49,282 Reduced 13.46%	316,808 Common Stock
Aug 25 2021	BUY Exercise of conversion of derivative security	$13,434,750 $179.13 p/Share	75,000 Added 17.0%	366,090 Common Stock
Aug 09 2021	SELL Bona fide gift	-	17,000 Reduced 5.52%	291,090 Common Stock
Jun 14 2021	SELL Bona fide gift	-	19,000 Reduced 5.81%	308,090 Common Stock
May 27 2021	SELL Bona fide gift	-	22,000 Reduced 6.3%	327,090 Common Stock
Feb 23 2021	SELL Payment of exercise price or tax liability	$63,269,325 $458.48 p/Share	137,998 Reduced 28.33%	349,090 Common Stock
Feb 23 2021	BUY Exercise of conversion of derivative security	$13,007,500 $52.03 p/Share	250,000 Added 33.92%	487,088 Common Stock
Dec 09 2020	BUY Grant, award, or other acquisition	-	2,439 Added 1.02%	237,088 Common Stock
May 27 2020	SELL Bona fide gift	-	73,100 Reduced 23.75%	234,649 Common Stock
May 21 2020	SELL Open market or private sale	$84,301,431 $566.5 p/Share	148,811 Reduced 32.54%	308,532 Common Stock
May 21 2020	SELL Open market or private sale	$452,464 $577.86 p/Share	783 Reduced 0.25%	307,749 Common Stock
May 20 2020	SELL Payment of exercise price or tax liability	$91,150,792 $570.97 p/Share	159,642 Reduced 25.87%	457,343 Common Stock
May 20 2020	BUY Exercise of conversion of derivative security	$9,571,875 $30.63 p/Share	312,500 Added 38.6%	497,063 Common Stock

PRV

P Roy Vagelos

Director

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account